Revvity Raises 2026 Guidance as Q3 Adjusted EPS Jumps 16.9% to $1.38
Revvity raised its full-year 2026 guidance after third-quarter adjusted earnings per share rose 16.9% to $1.38, with the life sciences and diagnostics company saying results came in "meaningfully ahead of our expectations."
Revenue grew 4.3% to $728.9 million from $698.9 million a year earlier, according to the earnings release Revvity filed with an 8-K on Tuesday. GAAP EPS from continuing operations rose to $0.56 from $0.41. Adjusted operating margin widened to 28.7% from 26.1%.
Revvity also reported results on a pro forma basis that exclude its Immunodiagnostics business in China, which it agreed on July 31 to sell for up to $200 million. On that basis, revenue rose 7.4% to $709.6 million, organic revenue grew 7%, and adjusted EPS climbed 21.2% to $1.37 from $1.13.
"With end market conditions continuing to improve, a strong pipeline of innovation, and the benefits of our transformation increasingly evident in our results, Revvity is extremely well positioned to capitalize on the opportunities ahead," President and CEO Prahlad Singh said in the release.
Life Sciences leads
Life Sciences revenue rose 10.8% to $380 million, with pro forma organic growth of 9%. Its adjusted operating income grew 17.8% to $119 million, and its adjusted operating margin widened to 31.5% from 29.5%.
Diagnostics revenue slipped 2.0% to $349 million on a reported basis, but pro forma revenue, excluding China IDX, rose 4% and pro forma organic revenue grew 5%. The segment's adjusted operating income jumped 16.9% to $104 million, lifting its margin to 29.9% from 25.1%.
Raised outlook
On a pro forma basis, Revvity now forecasts 2026 total revenue of an estimated $2.86 billion, organic revenue growth of an estimated 5% and adjusted EPS of $5.40 to $5.45, the company said. The guidance excludes China IDX.
The sale of China IDX, which accounted for an estimated 6% of Revvity's 2025 revenue, the company said, is expected to close by the end of 2027, subject to customary conditions and regulatory approvals. Revvity filed unaudited pro forma financial statements reflecting the sale with the same 8-K.
The company will hold an Investor Day on Nov. 13.
By the numbers
- Revenue: $728.9 million, up 4.3%
- Adjusted EPS: $1.38, up 16.9%
- GAAP EPS from continuing operations: $0.56, versus $0.41
- Pro forma organic revenue growth: 7%
- 2026 pro forma adjusted EPS outlook: $5.40 to $5.45, raised
- China IDX sale price: up to $200 million
Sources
- Revvity Form 8-K with third-quarter 2026 earnings release and pro forma financial information, filed Nov. 3, 2026 (accession 0000031791-26-000031)
This article is for informational and educational purposes only and is not investment advice. It is not a recommendation to buy or sell any security.
Disclaimer: This article was generated by IDD’s autonomous newsroom using super intelligence.